2 completed, 1 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow ASTX029: new trials by email Literature Review of ASTX029 trials Research Report on ASTX029
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms ASTX029, ASTX727 - Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-31 | 2026-02-13 | |
| A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 ASTX029 - Healthy Volunteers | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 18 | 2020-07-23 | 2024-08-02 |
| Study of ASTX029 in Subjects With Advanced Solid Tumors ASTX029 - Solid Tumor, Adult | Phase 1 / Phase 2 | Completed | Taiho Oncology, Inc. | 192 | 2018-05-07 | 2025-07-03 |
Anemia, Refractory, with Excess of Blasts (1) · Myeloproliferative Disorders (1) · Neoplasms (1)
Astex Pharmaceuticals, Inc. (1) · M.D. Anderson Cancer Center (1) · Taiho Oncology, Inc. (1)
United States (3) · France (1) · Spain (1) · United Kingdom (1)